Ptc Therapeutics Stock Piotroski F Score
| PTCT Stock | USD 25.97 0.65 2.57% |
PTC | Piotroski F Score |
At this time, it appears that PTC Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Increase |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | Higher Leverage |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
PTC Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to PTC Therapeutics is to make sure PTC is not a subject of accounting manipulations and runs a healthy internal audit department. So, if PTC Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if PTC Therapeutics' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.63 | 0.4928 |
|
| |||||
| Total Current Liabilities | 633.3 M | 603.1 M |
|
| |||||
| Non Current Liabilities Total | 2.2 B | 2.1 B |
|
| |||||
| Total Assets | 2 B | 1.9 B |
|
| |||||
| Total Current Assets | 1.3 B | 1.2 B |
|
|
PTC Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between PTC Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards PTC Therapeutics in a much-optimized way.
Click cells to compare fundamentals
About PTC Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 4.0B | 2.8B | 2.7B | 2.1B | 1.3B | |
| Enterprise Value | 2.5B | 4.2B | 2.5B | 3.0B | 1.9B | 1.2B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
PTC Therapeutics Investors Sentiment
The influence of PTC Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in PTC. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to PTC Therapeutics' public news can be used to forecast risks associated with an investment in PTC. The trend in average sentiment can be used to explain how an investor holding PTC can time the market purely based on public headlines and social activities around PTC Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
PTC Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for PTC Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average PTC Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on PTC Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PTC Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PTC Therapeutics' short interest history, or implied volatility extrapolated from PTC Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PTC Therapeutics Altman Z Score, PTC Therapeutics Correlation, PTC Therapeutics Valuation, as well as analyze PTC Therapeutics Alpha and Beta and PTC Therapeutics Hype Analysis. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.531 | Quarterly Revenue Growth 0.834 | Return On Assets (0.12) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.